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ORIGINAL RESEARCH
Objectives: Endothelial dysfunction is a common feature of type 2 diabetes. Recent studies
suggest that the B-vitamin folic acid exerts direct beneficial effects on endothelial function,
beyond the well known homocysteine lowering effects. Therefore, folic acid might represent
a novel “biomarker” of endothelial function. We sought to determine whether plasma levels
of folic acid determine endothelial-dependent vasodilation in patients with type 2 diabetes.
Methods: Forearm arterial blood flow (FABF) was measured at baseline and during intra-
brachial infusion of the endothelial-dependent vasodilator acetylcholine (15 µg/min) and the
endothelial-independent vasodilator sodium nitroprusside (2 µg/min) in 26 type 2 diabetic
patients (age 56.5 ± 0.9 years, means ± SEM) with no history of cardiovascular disease.
Results: FABF ratio (ie, the ratio between the infused and control forearm FABF) significantly
increased during acetylcholine (1.10 ± 0.04 vs 1.52 ± 0.07, p < 0.001) and sodium nitroprusside
(1.12 ± 0.11 vs 1.62 ± 0.06, p < 0.001) infusions. After correcting for age, gender, diabetes
duration, smoking, hypertension, body mass index, microalbuminuria, glycated hemoglobin,
low-density lipoprotein cholesterol, and homocysteine, multiple regression analysis showed
that plasma folic acid concentration was the only independent determinant (p = 0.037, R2 = 0.22)
of acetylcholine-mediated, but not sodium nitroprusside-mediated, vasodilatation.
Conclusions: Folic acid plasma concentrations determine endothelium-mediated
vasodilatation in patients with type 2 diabetes. These results support the hypothesis of a direct
effect of folic acid on endothelial function and the rationale for interventions aimed at increasing
folic acid levels to reduce cardiovascular risk.
Keywords: folic acid, homocysteine, endothelium, type 2 diabetes
Introduction
Impaired endothelial function is a common feature in type 2 diabetes (McVeigh et al
1992; Enderle et al 1998; Hogikyan et al 1998; Chowienczyk et al 1999; Kawagishi
et al 1999; Makimattila et al 1999; Rizzoni et al 2001). This might contribute to the
increased cardiovascular morbidity and mortality observed in type 2 diabetes by
accelerating the atherosclerotic process and enhancing the prothrombotic state
(Stehouwer et al 2002; Landmesser et al 2004).
Several factors including co-existing hypertension, obesity, insulin resistance,
hyperglycemia, hypercholesterolemia, and a proinflammatory state may account for
endothelial dysfunction in type 2 diabetes (Guerci et al 2001). Folic acid, a B-vitamin,
has recently gained considerable interest because of its potential to enhance endothelial
function in several pathological conditions including coronary artery disease, smoking,
familial hypercholesterolemia, and type 2 diabetes (Verhaar et al 1999; Chambers et
al 2000; Mangoni et al 2002; van Etten et al 2002). Recent evidence supports the
hypothesis that the effects of folic acid on endothelium may be “direct” (ie,
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Mangoni and Jackson 2002; Mangoni et al 2002). Folic acid
levels might represent a “biomarker” of endothelial function,
easily modifiable through safe, effective, and inexpensive
dietary and/or pharmacological interventions. Therefore, we
sought to determine whether folic acid plasma
concentrations affected endothelial function in a group of
patients with type 2 diabetes.
Methods
Subjects
Twenty-six patients with type 2 diabetes (age 56.5 ± 0.9
years, range 46–65; diabetes duration 5.5 ± 0.6 years,
means ± SEM) were recruited from diabetic and general
medical outpatient clinics and through local advertising. The
subjects had no history of angina, myocardial infarction,
stroke, or peripheral occlusive disease. Hypertension
(previous sphygmomanometric blood pressure values
> 130/80 mmHg and treatment with antihypertensive drugs)
was present in 16 patients. Antihypertensive treatment
included diuretics in 6 patients, angiotensin converting
enzyme inhibitors in 7, angiotensin II receptor antagonists
in 3, beta blockers in 7, Ca channel blockers in 4, and alpha
blockers in 2 patients. Antidiabetic treatment included oral
hypoglycemic agents and insulin in 4 patients, oral
hypoglycemic agents alone in 19, insulin alone in 2, and
diet alone in 1 patient. None of the subjects were on vitamin
supplements or drugs known to significantly alter folic acid
and/or homocysteine blood concentrations. Micro-
albuminuria, defined as urinary albumin–creatinine ratio
≥ 2.5 mg/mmol (men) or ≥ 3.5 mg/mmol (women), was
present in 8 subjects. The study had been approved by the
Local Research Ethics Committee. Each subject gave written
informed consent before starting the study.
Protocol
Investigations were performed in a temperature-controlled
laboratory (25–27 °C). The subjects were asked to abstain
from cigarette smoking and alcohol consumption from the
evening prior to the study. Each subject underwent 2 visits.
During visit 1, a physical examination and an electro-
cardiogram were performed, and blood pressure (BP) (mean
of three consecutive readings after the subject was resting
for 5 min) and heart rate (HR) were recorded. During visit
2, a fasting blood sample was taken (serum lipids and
glucose, glycated hemoglobin, full blood count,
homocysteine, and folic acid). Then, endothelial function
was assessed by the perfused forearm technique.
Forearm arterial blood flow
The brachial artery was cannulated using a 27-gauge cannula
connected via an epidural catheter to a infusion pump.
Forearm arterial blood flow (FABF) was measured
simultaneously in both arms (infused and control forearm)
by strain-gauge venous occlusion plethysmography (DE
Hokanson Inc, Bellevue, WA, USA). Measurements were
obtained at baseline after each subject rested supine for
20 min and during an 8-min intra-arterial infusion of
the endothelium-dependent vasodilator acetylcholine
(15 µg/min, Clinalfa, Switzerland). After a second baseline
was obtained, the endothelium-independent vasodilator
sodium nitroprusside (2 µg/min, David Bull Laboratories,
Warwick, UK) was infused. The doses of acetylcholine and
sodium nitroprusside used did not have any systemic effect
on BP and HR. FABF measurements were taken during the
final 2 min of each step. Circulation to the hands was
excluded 1 min before FABF measurement by inflating a
pediatric cuff around the wrist at 200 mmHg. Vasodilators
were stopped 5 days before FABF assessment. This wash-
out period was considered adequate, as the elimination half-
life of vasodilators ranged between 11 and 22 hours.
Folic acid and homocysteine
Serum
 folic acid was measured from fresh samples by
competitive protein binding enzyme immunoassays on the
Table 1 Baseline characteristics of the patients studied
Parameter Mean ± SEM (95% CI)





Diabetes duration (years) 5.5 ± 0.6 (4.3–6.7)
Body mass index (kg/m
2) 31.4 ± 1.1 (29.2–33.6)
Plasma glucose (mmol/L) 11.4 ± 0.8 (9.7–13.2)
Glycated hemoglobin (%) 8.3 ± 0.3 (7.6–8.9)
Serum folic acid (µg/L) 8.0 ± 0.6 (6.8–9.3)
Plasma homocysteine (µmol/L) 11.7 ± 0.4 (10.5–12.3)
Serum creatinine (mmol/L) 89 ± 3 (83–94)
Total cholesterol (mmol/L) 5.3 ± 0.1 (5.0–5.5)
HDL-cholesterol (mmol/L) 1.2 ± 0.1 (1.1–1.3)
LDL-cholesterol (mmol/L) 2.6 ± 0.1 (2.3–2.9)
Serum triglycerides (mmol/L) 3.3 ± 0.3 (2.7–4.0)
Systolic blood pressure (mmHg) 137 ± 3 (130–144)
Diastolic blood pressure (mmHg) 77 ± 2 (74–81)
Heart rate (beats/min) 74 ± 2 (69–79)
Abbreviations: CI, confidence interval; LDL, low-density lipoprotein; HDL, high-
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Centaur analyzer (Bayer Diagnostics, Newbury, UK). The
coefficient of variation was 5.2%. Fasting
 venous blood
samples were collected into tubes containing disodium
EDTA and tubes without anticoagulation. The samples were
centrifuged at 1800 g within 30 min, and the plasma and
serum separated and
 stored at –20 °C. Plasma homocysteine
was determined using a fluorescence polarization immuno-
assay on an IMX analyser (Abbott Diagnostics, Maidenhead,
UK) (Refsum et al 1989). Between-batch imprecision was
assessed at homocysteine concentrations of 7.0, 12.5, and
25.5 µmol/L, and coefficients of variation of 2.4%, 2.3%,
and 1.6% respectively were obtained (n = 19).
Statistical analysis
Data are presented as means ± SEM and 95% confidence
intervals. FABF values at baseline and during acetylcholine
infusion are expressed as ratio between the infused and
control forearm. FABF ratio differences between baseline
and acetylcholine infusion were assessed by paired Student
t test. Univariate analysis was performed by calculating the
correlation coefficient r between different parameters.
Determinants of endothelium-dependent vasodilatation were
identified by backward stepwise regression analysis. (SPSS
for Windows 11.0, SPSS Inc, Chicago, IL, USA). The factors
included in the model were age, gender, diabetes duration,
hypertension, smoking, glycated hemoglobin, body mass
index, microalbuminuria, low-density lipoprotein (LDL)
cholesterol, folic acid, and homocysteine concentrations. A
p-value < 0.05 indicated statistical significance.
Results
Baseline characteristics are illustrated in Table 1. No patient
had biochemical or clinical evidence of folic acid deficiency.
A significant increase in FABF ratio was observed during
acetylcholine (1.10 ± 0.04 baseline vs 1.52 ± 0.07 during
acetylcholine, p < 0.001) and sodium nitroprusside
(1.12 ± 0.11 baseline vs 1.62 ± 0.06 during sodium
nitroprusside, p < 0.001), indicating significant vaso-
dilatation in the infused arm. Univariate analysis of baseline
clinical and biochemical parameters did not show any
significant relationship apart from a negative correlation
between homocysteine and glycated hemoglobin
concentrations (Table 2). After correcting for age, gender,
diabetes duration, smoking, hypertension, body mass index,
microalbuminuria, glycated hemoglobin, LDL-cholesterol,
and homocysteine, multivariate regression analysis showed
that folic acid concentration was the only significant and
independent determinant of acetylcholine-mediated
endothelium-dependent, but not of sodium nitroprusside-
mediated endothelium-independent, vasodilatation
(p = 0.037, R2 = 0.22; Tables 3 and 4).
Discussion
Folic acid levels significantly and independently determined
forearm endothelium-dependent, but not endothelium-
independent, vasodilatation in a group of stable patients with
type 2 diabetes. Therefore, blood concentrations of this B-
vitamin might represent a biologically and clinically useful
marker of endothelial function in these patients.
Table 2 Univariate analysis with correlation coefficients
Parameter Folate BMI LDL-Chol Hcy Age Diab dur HbA1c
Folate – –0.011 –0.068 –0.170 –0.058 –0.288 –0.273
p 0.956 0.754 0.438 0.780 0.153 0.178
BMI –0.011 – 0.352 –0.009 0.000 0.252 –0.059
p 0.956 0.091 0.969 1.000 0.215 0.776
LDL-Chol –0.068 0.352 – 0.039 0.021 0.182 –0.089
p 0.754 0.091 0.864 0.923 0.394 0.678
Hcy –0.170 –0.009 0.039 – 0.345 0.204 –0.498
p 0.438 0.969 0.864 0.107 0.351 0.016
Age –0.058 0.000 0.021 0.345 – 0.160 –0.219
p 0.780 1.000 0.923 0.107 0.435 0.282
Diab dur –0.288 0.252 0.182 0.204 0.160 – 0.304
p 0.153 0.215 0.394 0.351 0.435 0.132
HbA1c –0.273 –0.059 –0.089 –498 –0.219 0.304 –
p 0.178 0.776 0.678 0.016 0.282 0.132
Abbreviations: BMI, body mass index; LDL-Chol, low-density lipoprotein cholesterol; Hcy, homocysteine; Diab dur, diabetes duration; HbA1c, glycated hemoglobin; p,
probability.Vascular Health and Risk Management 2005:1(1) 82
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Endothelial dysfunction is an independent predictor of
mortality in patients with type 2 diabetes followed up for 9
years, even after correcting for urinary albumin excretion
and markers of inflammation (Stehouwer et al 2002).
Therefore, enhancement of endothelial function might
provide significant cardiovascular protection.
The ameliorative effects of folic acid supplementation
on endothelial function have been traditionally ascribed to
its homocysteine lowering effects (Mangoni and Jackson
2002). It is well established that homocysteine acutely and
chronically impairs endothelial function by inhibiting the
synthesis and release of nitric oxide and enhancing the
production of superoxide (Zhang et al 2000; Mangoni and
Jackson 2002; Weiss et al 2003). Therefore, lowering of
homocysteine levels might explain the enhancement of
endothelial function following folic acid treatment (Bellamy
et al 1999; Woo et al 1999).
Recent studies, however, support the hypothesis that folic
acid exerts direct effects on the endothelium (Doshi et al
2002; Mangoni et al 2002). There is in vitro evidence that
5-methyltetrahydrofolate, the active form of folic acid,
interacts with the enzyme endothelial nitric oxide synthase
(eNOS) in a fashion analogous, yet independent, of the co-
factor tetrahydrobiopterin to enhance endothelial function
(Hyndman et al 2002).
The results of our study suggest that folic acid, by
directly interacting with eNOS, directly modulates NO
production and endothelial function, independently of
established markers of endothelial dysfunction and
cardiovascular disease in type 2 diabetes. Of note, none of
the study subjects had folic acid deficiency, suggesting that
a “relative” rather than an “absolute” deficiency may already
provide adverse effects on endothelial function. This might
have important clinical implications, as folic acid levels can
be easily and safely increased by dietary intervention
and/or vitamin supplementation (Lucock 2004).
Our patients were on several antihypertensive and
hypoglycaemic drugs affecting endothelial function, thus
potentially limiting data interpretation. Although
antihypertensive vasodilators were stopped at least 5 half-
lives before the study day, we ran another regression analysis
Table 3 Backward multiple regression analysis (last 6 steps) of
changes in maximal endothelial-dependent vasodilatation during
acetylcholine infusion
Model Beta t Sig R R2
Gender –0.312 –1.251 0.233 0.72 0.52
Body mass index –0.328 –1.411 0.182
Smoking 0.378 1.806 0.094
LDL-cholesterol –0.298 –1.452 0.170
Homocysteine 0.244 1.193 0.254
Folic acid 0.645 3.3037 0.010
Gender –0.356 –1.424 0.176 0.68 0.47
Body mass index –0.335 –1.420 0.178
Smoking 0.329 1.580 0.136
LDL-cholesterol –0.288 –1.380 0.189
Folic acid 0.608 2.850 0.013
Gender –0.316 –1.234 0.236 0.63 0.40
Body mass index –0.413 –1.750 0.101
Smoking 0.325 1.518 0.150
Folic acid 0.600 2.730 0.015
Body mass index –0.261 –1.275 0.220 0.58 0.33
Smoking 0.238 1.159 0.264
Folic acid 0.493 2.402 0.29
Body mass index –0.244 –1.185 0.252 0.53 0.28
Folic acid 0.465 2.260 0.037
Folic acid 0.469 2.253 0.037 0.47 0.22
NOTE: Dependent variable = changes in FABF ratio during acetylcholine infusion.
Abbreviations: Beta, regression coefficient; t, regression coefficient; Sig,
significance; R, R statistic; R2, R squared; FABF, forearm arterial blood flow.
Table 4 Backward multiple regression analysis (last 6 steps) of
changes in maximal endothelial-independent vasodilatation
during sodium nitroprusside infusion
Model Beta t Sig R R2
Smoking 0.415 1.844 0.088 0.68 0.47
Microalbuminuria –0.383 –1.691 0.115
LDL-cholesterol –0.301 1.424 0.178
Age 0.467 1.954 0.073
Gender 0.258 1.170 0.263
Hypertension 0.443 1.793 0.096
Smoking 0.442 1.952 0.071 0.64 0.41
Microalbuminuria –0.384 –1.676 0.116
LDL-cholesterol –0.369 –1.797 0.094
Age 0.408 1.724 0.107
Hypertension 0.396 1.604 0.131
Smoking 0.342 1.493 0.156 0.55 0.30
Microalbuminuria –0.222 –1.025 0.321
LDL-cholesterol –0.367 –1.701 0.110
Age 0.258 1.129 0.277
Smoking 0.329 1.439 0.169 0.50 0.25
LDL-cholesterol –0.356 –1.647 0.119
Age 0.263 1.148 0.268
Smoking 0.242 1.111 0.282 0.44 0.19
LDL-cholesterol –0.367 –1.687 0.110
LDL-cholesterol –0.367 –1.676 0.111 0.36 0.13
NOTE: Dependent variable = changes in FABF ratio during sodium nitroprusside
infusion. Abbreviations: Beta, regression coefficient; t, regression coefficient; Sig,
significance; R, R statistic; R2, R squared; LDL, low-density lipoprotein.Vascular Health and Risk Management 2005:1(1) 83
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to study the effect of antihypertensive and hypoglycemic
treatment. None of these drugs affected the relationship
between folic acid levels and endothelial-dependent
vasodilatation (data not shown).
The limitations of our study are related to the relatively
small sample size, the lack of data on oxidative stress
markers to further support a beneficial effect of folic acid
on eNOS activity, and the absence of “hard” end points such
as cardiovascular morbidity and mortality. Larger
randomized controlled studies are urgently needed to
demonstrate whether folic acid reduces cardiovascular risk
in type 2 diabetes.
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